TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05386277

Intervention type: DEVICE
Group type: OTHER
Intervention: TufTex Single Lumen Embolectomy Catheter
Description: The SLC Embolectomy Catheter is indicated for the removal of arterial emboli and thrombi
Study: NCT04654546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound abdominal scan
Description: A complete ultrasound scan of the abdominal organs using a clinical ultrasound device in the Imaging Institute at Haemek medical center. The ultrasound images will be visually coupled to previous CT images of the same patient at the time of the examination, using a Fusion system located in the ultrasound device mentioned above.~The coupled CT and ultrasound images will be encoded and be sent to the SAMPL laboratory in Weizmann institute, there it will serve as a learning platform for the artificial intelligence system.
Study: NCT05759520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (multivalent conjugate)
Description: the 2-month-old experimental group and the 3-month-old group received the experimental vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (multivalent conjugate)
Description: the 2-month-old experimental group and the 3-month-old group received the experimental vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: the 2-month-old control group received the active control vaccine
Study: NCT05443438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 3D-2D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 2D-3D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 2D-2D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
Study: NCT06638385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE + SPACE SHIELD
Description: Patients receive a DCE with implantation of a space-expanding shield.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCE + CP
Description: Patients in the control group receive a DCE similar to the intervention group, but without implantation of a space-expanding shield. Cranioplasty (CP) is performed after \~ 90 days in the customary manner.
Study: NCT05963386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-FAPI radionuclide therapy
Description: radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.3 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
Study: NCT06443398

Intervention type: OTHER
Intervention: There is no intervention in the study
Description: There is no intervention in the study

Intervention type: OTHER
Intervention: There is no intervention in the study
Description: There is no intervention in the study
Study: NCT06145581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care (home-based physical activity)
Description: Receive health coaching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in home-based physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone interview
Description: Participate in a telephone interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Monitoring
Description: Undergo remote monitoring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Monitoring
Description: Monitor physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study: NCT05867550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550 MG
Description: Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550 MG
Description: Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
Study: NCT04933084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative Opioid Education
Description: The pre-operative education in the text handout and pre-recorded video will include the topics of:~1. Description of expected postoperative pain after robotic prostatectomy and typical opioid consumption after RARP.~2. Efficacy of non-opioid multimodal analgesia and recommendation to take nonopioid alternatives prior to prescribed opioids.~3. Adverse short- and long-term effects of opioids including nausea, vomiting, sedation, hypoventilation, hypotension, dizziness, constipation, depression, and addiction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative Opioid Education
Description: The pre-operative education in the text handout and pre-recorded video will include the topics of:~1. Description of expected postoperative pain after robotic prostatectomy and typical opioid consumption after RARP.~2. Efficacy of non-opioid multimodal analgesia and recommendation to take nonopioid alternatives prior to prescribed opioids.~3. Adverse short- and long-term effects of opioids including nausea, vomiting, sedation, hypoventilation, hypotension, dizziness, constipation, depression, and addiction.
Study: NCT05896722

Intervention type: OTHER
Intervention: Core muscle endurance
Description: Trunk flexion, trunk extension, side bridge exercises and prone bridge test developed by McGill will be used to evaluate core muscle endurance.

Intervention type: OTHER
Intervention: Core muscle endurance
Description: Trunk flexion, trunk extension, side bridge exercises and prone bridge test developed by McGill will be used to evaluate core muscle endurance.

Intervention type: OTHER
Intervention: Upper extremity muscle strength
Description: Isometric muscle strength assessment of the shoulder, elbow and wrist muscles will be performed with a hand-held dynamometer.

Intervention type: OTHER
Intervention: Upper extremity muscle strength
Description: Isometric muscle strength assessment of the shoulder, elbow and wrist muscles will be performed with a hand-held dynamometer.

Intervention type: OTHER
Intervention: Grip strength
Description: Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.

Intervention type: OTHER
Intervention: Grip strength
Description: Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.

Intervention type: OTHER
Intervention: Pinch strength
Description: Pinch strength will be evaluated with a pinchmeter in three positions.

Intervention type: OTHER
Intervention: Pinch strength
Description: Pinch strength will be evaluated with a pinchmeter in three positions.

Intervention type: OTHER
Intervention: Alternate hand-wall toss test
Description: To measure hand-eye coordination, it is performed by changing hands by throwing and catching the ball against the wall.

Intervention type: OTHER
Intervention: Alternate hand-wall toss test
Description: To measure hand-eye coordination, it is performed by changing hands by throwing and catching the ball against the wall.
Study: NCT04388904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
Description: Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.
Study: NCT05207917

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: In Roux-en-Y gastric bypass (RYGB), the left crus will be dissected free, any hiatal hernia left in place. The minor curvature is opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch will be created by firing one horizontal and two vertical staple loads. The ligament of Treitz is then identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one linear stapler (full length of the stapler), creating an antecolic, antegastric alimentary limb. The opening will be closed using a single row, running absorbable suture. An entero-enteroanastomosis will be made 120 cm distal of the gastro-enteroanastomosis. The introductory opening is closed with a single row, running absorbable suture. The small intestine will be divided with one load between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a biliopancreatic limb of 60 cm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: In sleeve gastrectomy (SG) a large part (80%) of the ventricle is removed. The greater curvature will be dissected free starting 4-5 cm from the pylorus up to the angle of Hiss. The left crus is then visualized and inspected for hiatal hernia. Small sliding hernias and wide hiatus are left in situ. The ventricle will then be lifted and any adhesions in the lesser sac divided. A 35 Fr bougie is placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads are always green or purple, while blue or tan loads are used for the rest of the ventricle. The last stapler is placed 5 mm laterally to the angle of Hiss. The staple line will then be inspected and secured with clips for additional haemostasis, no oversewing or buttressing material is routinely used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single anastomosis sleeve ileal (SASI) bypass
Description: The SASI bypass will performed with a similar entry of the abdominal cavity. A 6-port set up and a liver retractor is utilized. The small bowel is measured 300cm from the ileocecal valve, in sequences of 10cm, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. The antrum is opened ventrally 5 cm proximal to the pylorus, just below the horizontal axis of canalis pylori. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 2.5 cm of the 45 mm stapler device is used for firing the anastomosis, which is completed with a 2-0 PDS running suture. The fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
Study: NCT05565443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Brain Barrier Disruption - Functional
Description: Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Brain Barrier Disruption - Functional
Description: Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease
Study: NCT05867550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550 MG
Description: Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebeverine 135 MG
Description: Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
Study: NCT01609439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 800 units for 4 weeks preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05725408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy-informed group eating intervention protocol (telehealth)
Description: A 10-week, skills-based group eating intervention. Online/telehealth meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical behavior therapy-informed group eating intervention protocol (in-person)
Description: A 10-week, skills-based group eating intervention. In-person meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments, online) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
Study: NCT05591612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt replacement seasoning (50% salt and 50% MSG) mix
Description: Individuals in this group were provided a seasoning that replaced 50 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 50/50 MSG Mix to be added to vegetables in diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt replacement seasoning (70% salt and 30% MSG) mix
Description: Individuals in this group were provided a seasoning that replaced 30 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 70/30 MSG Mix to be added to vegetables in diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NaCl (sodium chloride/table salt)
Description: Individuals in this group were asked to use normal seasoning of regular salt. This study assessed the vegetable intake using table salt to be added to vegetables in diet.
Study: NCT05867550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium Husk
Description: Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline Hydrochloride 25 MG
Description: Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
Study: NCT06478225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGT007H Cell Injection
Description: Intervention roughly goes through 3 phases (the day of cell infusion is defined as day 0, d0):~1. Apheresis and baseline period: Eligible subjects are enrolled for leukapheresis to prepare BGT007H cell injection solution, and baseline assessment is performed from after apheresis to before preconditioning.~2. Preconditioning (d-5\~d-3): Patients begin preconditioning (FC regimen) 5 days before BGT007H cell administration. A 2-day rest and observation period is conducted after preconditioning.~   The FC regimen is as follows:~  * Fludarabine: 25\~30mg/m2/d, intravenous infusion, once a day, for 3 consecutive days;~  * Cyclophosphamide: 250\~350mg/m2/d, intravenous infusion, once a day, for 3 consecutive days.~3. Cell infusion (d0) and DLT observation period (d0\~d28).
Study: NCT04105946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine administration intraoperatively in combination with other drugs used in OFA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: remifentanil administration intraoperatively in combination with other drugs used in TIVA
Study: NCT06304805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cycle 1: treatment drug
Description: for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cycle 1: treatment drug
Description: for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cycle 1: treatment drug
Description: for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
Study: NCT05901415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined anterior lumbar plexus and lateral sacral plexus block in a semi-supine position
Description: We proposed a modified approach of combined anterior LPB and lateral SPB with the patients posed in a semi-supine position aiming to reduce the pain and discomfort induced by position changing effectively.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Combined anterior lumbar plexus and lateral sacral plexus block in a classical position.
Description: Patients posed in a classical position and received combined anterior LPB and lateral SPB.
Study: NCT05064553

Intervention type: DEVICE
Intervention: Study CT/MRI Imaging
Description: Subjects with negative ultrasound will be sent for a study CT/MRI.

Intervention type: DEVICE
Intervention: Standard of Care CT/MRI Imaging
Description: Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up as well as other procedures as needed.

Intervention type: DEVICE
Intervention: Standard of Care CT/MRI Imaging
Description: Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up as well as other procedures as needed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oncoguard™ Liver Test
Description: Subjects will have a blood sample collected for the Oncoguard™ Liver Test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oncoguard™ Liver Test
Description: Subjects will have a blood sample collected for the Oncoguard™ Liver Test.
Study: NCT05330741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designed Physical Therapy Program
Description: The designed physical therapy program include gentle stretching exercises, static muscle contraction, facilitation of trunk control from different positions, balance training from different positions on tilting board, facilitation of righting, protective and equilibrium reactions from different positions, facilitation of standing from different positions, gait training and, climbing stairs up and down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designed Physical Therapy Program
Description: The designed physical therapy program include gentle stretching exercises, static muscle contraction, facilitation of trunk control from different positions, balance training from different positions on tilting board, facilitation of righting, protective and equilibrium reactions from different positions, facilitation of standing from different positions, gait training and, climbing stairs up and down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designed Physical Therapy Program
Description: The designed physical therapy program include gentle stretching exercises, static muscle contraction, facilitation of trunk control from different positions, balance training from different positions on tilting board, facilitation of righting, protective and equilibrium reactions from different positions, facilitation of standing from different positions, gait training and, climbing stairs up and down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration
Description: The designed physical therapy program (mentioned before)~+ Whole-body vibration (WBV) training, child will be asked to stand with slightly flexed knees (30 degrees of knee flexion), and both feet will be placed at an equal distance from the center of the platform to achieve an equal distribution of body weight over both feet. The device will set to produce a peak-to-peak sinusoidal vibration with an amplitude of 2 mm and a vibration frequency ranged from 25 to 30 Hz. WBV will applied for (30 sec. of WBV, 1 min rest, 10 repetitions), (45 sec. of WBV, 1 min rest, 10 repetitions), (60 sec. of WBV, 1 min rest, 10 repetitions) in the 1st, 2nd. and 3rd. months respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gravity Force Stimulation
Description: The designed physical therapy program (mentioned before)~+ Gravity force stimulation child will be asked to maintain his balance on GFS during each of the following positions as a progression (standing and walking on the surface of two beams connecting the two boxes - standing and walking crossly on the surface of one beam connecting the two boxes - standing and walking sideward on the surface of one beam connecting the two boxes - standing and walking on the edge of the two beams - standing and walking on the edge of one beam: most difficult)
Study: NCT04747067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOPURE 260HF dialyzer
Description: Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOPURE 260HF dialyzer
Description: Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)
Study: NCT05755607

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic pancreaticoduodenectomy
Description: The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robot Pancreaticoduodenectomy
Description: The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
Study: NCT06098703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARD (Comfort Ask Relax Distract)
Description: CARD is a vaccine delivery framework/protocol to plan and deliver vaccinations
Study: NCT05484154

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC
Description: 3K3A-APC, diluted in 0.9% sodium chloride in water, given at 100 mL IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC
Description: 3K3A-APC, diluted in 0.9% sodium chloride in water, given at 100 mL IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC
Description: 3K3A-APC, diluted in 0.9% sodium chloride in water, given at 100 mL IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, 0.9% sodium chloride in water, given at 100 mL IV infusion
Study: NCT05922319

Intervention type: OTHER
Intervention: Computerized cognitive training with different training doses
Description: The training dose was defined as training frequency (number of training days per week) and average training duration per training day. The daily dose was divided into 13 categories with an interval of 5 minutes and the training frequency has 7 categories according to the number of training days per week.